Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
CD22-targeted antibody-drug conjugate
DRUG CLASS:
CD22-targeted antibody-drug conjugate
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
inotuzumab ozogamicin (28)
TRPH-222 (1)
OXS-1550 (0)
ADCT-602 (0)
RG7593 (0)
inotuzumab ozogamicin (28)
TRPH-222 (1)
OXS-1550 (0)
ADCT-602 (0)
RG7593 (0)
›
Associations
(29)
News
Trials
VERI cancer hierarchy
Reset Filters
CD22 positive
B Acute Lymphoblastic Leukemia
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
inotuzumab ozogamicin
Sensitive: A2 - Guideline
inotuzumab ozogamicin
Sensitive
:
A2
inotuzumab ozogamicin
Sensitive: A2 - Guideline
inotuzumab ozogamicin
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
inotuzumab ozogamicin
Sensitive: A2 - Guideline
inotuzumab ozogamicin
Sensitive
:
A2
inotuzumab ozogamicin
Sensitive: A2 - Guideline
inotuzumab ozogamicin
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
bosutinib + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
bosutinib + inotuzumab ozogamicin
Sensitive
:
C2
bosutinib + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
bosutinib + inotuzumab ozogamicin
Sensitive
:
C2
CD22 positive
B Acute Lymphoblastic Leukemia
CD22 positive
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
blinatumomab + inotuzumab ozogamicin
Sensitive
:
C2
blinatumomab + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
blinatumomab + inotuzumab ozogamicin
Sensitive
:
C2
CD22 expression
B Acute Lymphoblastic Leukemia
CD22 expression
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
inotuzumab ozogamicin
Sensitive
:
C2
inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
inotuzumab ozogamicin
Sensitive
:
C2
CD22 expression
B Acute Lymphoblastic Leukemia
CD22 expression
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
blinatumomab + inotuzumab ozogamicin
Sensitive
:
C2
blinatumomab + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
blinatumomab + inotuzumab ozogamicin
Sensitive
:
C2
MLL rearrangement
Acute Lymphocytic Leukemia
MLL rearrangement
Acute Lymphocytic Leukemia
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Resistant
:
C3
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Resistant
:
C3
MLL rearrangement
Acute Lymphocytic Leukemia
MLL rearrangement
Acute Lymphocytic Leukemia
inotuzumab ozogamicin
Resistant: C3 – Early Trials
inotuzumab ozogamicin
Resistant
:
C3
inotuzumab ozogamicin
Resistant: C3 – Early Trials
inotuzumab ozogamicin
Resistant
:
C3
TP53 mutation
B Acute Lymphoblastic Leukemia
TP53 mutation
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Resistant
:
C3
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Resistant
:
C3
TP53 mutation + IKZF3 mutation
B Acute Lymphoblastic Leukemia
TP53 mutation + IKZF3 mutation
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
TP53 mutation + IKZF1 mutation
B Acute Lymphoblastic Leukemia
TP53 mutation + IKZF1 mutation
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
IKZF3 mutation
B Acute Lymphoblastic Leukemia
IKZF3 mutation
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
TP53 deletion
B Acute Lymphoblastic Leukemia
TP53 deletion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
IKZF1 mutation
B Acute Lymphoblastic Leukemia
IKZF1 mutation
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
TP53 mutation
B Acute Lymphoblastic Leukemia
TP53 mutation
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
CD22 overexpression
Acute Lymphocytic Leukemia
CD22 overexpression
Acute Lymphocytic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
CD22 underexpression + BCL2 overexpression
Acute Lymphocytic Leukemia
CD22 underexpression + BCL2 overexpression
Acute Lymphocytic Leukemia
inotuzumab ozogamicin
Resistant: C3 – Early Trials
inotuzumab ozogamicin
Resistant
:
C3
inotuzumab ozogamicin
Resistant: C3 – Early Trials
inotuzumab ozogamicin
Resistant
:
C3
CRLF2 overexpression
B Acute Lymphoblastic Leukemia
CRLF2 overexpression
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
CRLF2 overexpression
B Acute Lymphoblastic Leukemia
CRLF2 overexpression
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Sensitive
:
C3
blinatumomab + inotuzumab ozogamicin
Sensitive: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Sensitive
:
C3
TP53 mutation
Diffuse Large B Cell Lymphoma
TP53 mutation
Diffuse Large B Cell Lymphoma
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
CD79B mutation
Diffuse Large B Cell Lymphoma
CD79B mutation
Diffuse Large B Cell Lymphoma
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
MYD88 mutation
Diffuse Large B Cell Lymphoma
MYD88 mutation
Diffuse Large B Cell Lymphoma
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
CD58 expression
B Acute Lymphoblastic Leukemia
CD58 expression
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
inotuzumab ozogamicin
Sensitive
:
C3
CD22 positive
T Cell Non-Hodgkin Lymphoma
CD22 positive
T Cell Non-Hodgkin Lymphoma
TRPH-222
Sensitive: D – Preclinical
TRPH-222
Sensitive
:
D
TRPH-222
Sensitive: D – Preclinical
TRPH-222
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login